(2S)-2-amino-N-[(1S)-1-[(4R,5R)-5-[(1S)-1-[[(2S)-2-amino-3-methylbutanoyl]amino]-2-phenylethyl]-2,2-dimethyl-1,3-dioxolan-4-yl]-2-phenylethyl]-3-methylbutanamide | 204907-78-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-amino-N-[(1S)-1-[(4R,5R)-5-[(1S)-1-[[(2S)-2-amino-3-methylbutanoyl]amino]-2-phenylethyl]-2,2-dimethyl-1,3-dioxolan-4-yl]-2-phenylethyl]-3-methylbutanamide
• CAS: 204907-78-8
• 化学式: C₃₁H₄₆N₄O₄
• 分子量: 538.731
• InChiKey: QPMVRFAIFOYHHV-FZFXNXQRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  39
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  129
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2S)-2-amino-N-[(1S)-1-[(4R,5R)-5-[(1S)-1-[[(2S)-2-amino-3-methylbutanoyl]amino]-2-phenylethyl]-2,2-dimethyl-1,3-dioxolan-4-yl]-2-phenylethyl]-3-methylbutanamide 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 对甲苯磺酸 、 三乙胺 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 24.25h， 生成 [(S)-1-((S)-1-{(1S,2R,3R,4S)-1-Benzyl-4-[(S)-2-((S)-2-benzyloxycarbonylamino-hexanoylamino)-3-methyl-butyrylamino]-2,3-dihydroxy-5-phenyl-pentylcarbamoyl}-2-methyl-propylcarbamoyl)-pentyl]-carbamic acid benzyl ester
  参考文献：
  名称：

  Development of a New Type of Protease Inhibitors, Efficacious against FIV and HIV Variants

  摘要：

  Based on the structural analysis of FIV protease and drug-resistant HIV proteases and molecular modeling, a new type of inhibitors with a small P3 residue has been developed. These inhibitors are effective against HIV and its drug-resistant mutants, as well as SIV and FIV. Modification of existing HIV protease inhibitors by reducing the size of the P3 residue has the same effect. This finding provides a new strategy for the development of HIV protease inhibitors effective against the wild-type and drug-resistant mutants. It further supports the use of FIV protease as a useful model for drug-resistant HIV proteases, which often have a more constricted binding region for the P3 group or the combined P3 and P1 groups.

  DOI：

  10.1021/ja982893p

文献信息

• Anti-coronavirus compounds
  申请人：Wong Chi-Huey

  公开号：US20060160866A1

  公开（公告）日：2006-07-20

  A method of treating coronavirus infection. The method includes administering to a subject suffering from or being at risk of suffering from such infection an effective amount of a compound of formula (I). Each variable in this formula is defined in the specification.

  治疗冠状病毒感染的方法。该方法包括向患有或有患上这种感染风险的受试者施用化合物(I)的有效剂量。该公式中的每个变量在规范中有定义。
• US8481571B2
  申请人：——

  公开号：US8481571B2

  公开（公告）日：2013-07-09
• Development of a New Type of Protease Inhibitors, Efficacious against FIV and HIV Variants
  作者：Taekyu Lee、Van-Duc Le、Dongyeol Lim、Ying-Chuan Lin、Garrett M. Morris、Andrew L. Wong、Arthur J. Olson、John H. Elder、Chi-Huey Wong

  DOI：10.1021/ja982893p

  日期：1999.2.1

  Based on the structural analysis of FIV protease and drug-resistant HIV proteases and molecular modeling, a new type of inhibitors with a small P3 residue has been developed. These inhibitors are effective against HIV and its drug-resistant mutants, as well as SIV and FIV. Modification of existing HIV protease inhibitors by reducing the size of the P3 residue has the same effect. This finding provides a new strategy for the development of HIV protease inhibitors effective against the wild-type and drug-resistant mutants. It further supports the use of FIV protease as a useful model for drug-resistant HIV proteases, which often have a more constricted binding region for the P3 group or the combined P3 and P1 groups.